A meta-analysis showed that male RCC patients benefited more from immunotherapy [9], which might be explained by abundant infiltrated CD8+ T-cells in the TME of male RCC, which can be mobilized after ICIs administration. Here, CD8A is linked to renal cell carcinoma.